Germany is keen to promote the use of generic drugs as it battles soaring drug spending. Therefore, while the sales of innovative drugs may experience a decline in Germany as a result of the patent cliff and the subsequent rise in generic competition, Business Monitor International believe the high consumption of generic medicines by volume (75% in 2009) highlights opportunities for generic drugmakers in Europe's largest drug market.
However, BMI notes that downward pressure on the prices of generic medicines as a result of tenders raising the level of competition, and ultimately the commoditization of off-patent medicines, draws attention to the inherent challenges for generic drugmakers looking to profit from the government's focus on cost-containment within the health care sector.
Prescription of generic medicines has increased
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze